1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gamida Cell Ltd.
  6. Company
    GMDA   IL0011552663

GAMIDA CELL LTD.

(GMDA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Gamida Cell Ltd.
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).

Number of employees : 168 people.
Managers
Name Title Age Since
Julian Adams, Dr. Chief Executive Officer & Director 66 2018
Shai Lankry Chief Financial Officer 44 2018
Ronit Simantov, Dr. Chief Medical & Scientific Officer 56 -
Yona Geffen, Dr. Vice President-Research & Development - 2020
Michele I. Korfin Chief Operating & Commercial Officer 50 2020
Joshua F. Patterson Chief Compliance Officer & General Counsel 45 2021
Heather DiVecchia Chief of Staff - 2019
Tzvi Palash Chief Manufacturing Officer 64 -
Vladimir Melnikov Senior VP-Global Operations & Manufacturing - 2021
Jas Uppal, Dr. Chief Regulatory & Quality Officer 53 2020
Members of the board
Name Title Age Since
Robert I. Blum Chairman 57 2018
Kenneth I. Moch Independent Non-Executive Director 66 2016
Ofer Gonen Independent Director 47 2015
Shawn Cline Tomasello Independent Director 62 2019
Stephen T. Wills Independent Director 64 2019
Julian Adams, Dr. Chief Executive Officer & Director 66 2018
Anat Cohen-Dayag, Dr. Director 54 2022
Naama Halevi-Davidov, Dr. Director 50 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 60,021,415 41,901,966 69.8% 75,117 0.1% 69.8%
Shareholders
NameEquities%
Clal Biotechnology Industries Ltd. 9,744,857 16.2%
Federated Global Investment Management Corp. 5,128,300 8.55%
Fidelity Management & Research Co. LLC 4,587,704 7.65%
Novartis AG 4,336,759 7.23%
Rock Springs Capital Management LP 2,154,300 3.59%
Wellington Management Co. LLP 1,894,526 3.16%
Elbit Imaging Ltd. 1,828,373 3.05%
I.H.C.V Israel Healthcare Ventures Ltd. 1,782,847 2.97%
Stonepine Capital Management LLC 1,724,201 2.87%
BVF Partners LP 1,343,667 2.24%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gamida Cell Ltd.